ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Aberrantly expressed glycosyltransferases are characteristic of a number of diseases, but detecting specific glycosyltransferases for diagnostic use is notoriously difficult. The next best thing would be to detect abnormal glycans produced by the disease-related glycosyltransferases, but single glycans cannot be directly connected to the activity of specific glycosyltransferases. A new “bottom up” (component analysis) technique devised by Chad R. Borges of the Biodesign Institute at Arizona State University and coworkers could help resolve this logjam (Anal. Chem., DOI: 10.1021/ac3035579). Noting that unusual disease-related glycans contain unique amounts of “glycan nodes”—characteristic combinations of specific sugars and linkage types—they developed a GC/MS technique to detect node levels as stand-ins for the disease-related glycosyltransferases that produce them. They use the technique to diagnose lung cancer in blood plasma samples with 76 to 88% reliability. They believe the reliability can be improved and the technique can be extended to diagnose a variety of other conditions.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter